LMR Partners’s Novo Nordisk NVO Stock Holding History

LMR Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.35M	Sell	63,871 -36,129	-36%	-$1.71M	0.01%	824
2025 Q4	$5.09M	Buy	100,000 +98,594	+7,012%	+$5.04M	0.01%	567
2025 Q3	$78K	Buy	+1,406	New	+$82.3K	﹤0.01%	1294
2025 Q2	–	Sell	-40,000	Closed	-$2.72M	–	1566
2025 Q1	$2.78M	Buy	40,000 +15,001	+60%	+$1.24M	0.03%	580
2024 Q4	$2.15M	Sell	24,999 -38,534	-61%	-$4.17M	0.02%	583
2024 Q3	$7.56M	Buy	63,533 +5,398	+9%	+$720K	0.06%	272
2024 Q2	$8.3M	Sell	58,135 -503	-0.9%	-$66.7K	0.07%	240
2024 Q1	$7.53M	Buy	58,638 +54,404	+1,285%	+$6.48M	0.08%	232
2023 Q4	$438K	Buy	+4,234	New	+$419K	0.01%	662
2023 Q3	–	Sell	-71,686	Closed	-$6.31M	–	1007
2023 Q2	$5.8M	Buy	+71,686	New	+$5.86M	0.06%	241
2022 Q4	–	Sell	-14,400	Closed	-$717K	–	1221
2022 Q3	$717K	Sell	14,400 -50,000	-78%	-$2.68M	0.01%	814
2022 Q2	$3.59M	Buy	+64,400	New	+$3.57M	0.06%	359

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

LMR Partners's NVO Position: Q1 2026 in Review

LMR Partners reduced its Novo Nordisk (NVO) stake by 36% in Q1 2026, selling an estimated $1.71M and leaving 63,871 shares worth $2.35M. The position accounts for 0.01% of the portfolio, ranked #824.

LMR Partners first reported a position in NVO in Q2 2022 and has held it in 12 quarters since. The position peaked at $8.3M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

LMR Partners held 63,871 shares of Novo Nordisk worth $2.35M as of Q1 2026.
LMR Partners sold 36,129 Novo Nordisk shares in Q1 2026, an estimated $1.71M.
Novo Nordisk made up 0.01% of LMR Partners's portfolio in Q1 2026, its #824 holding.
LMR Partners first reported a position in Novo Nordisk in Q2 2022 and has held it in 12 quarters since.
LMR Partners's Novo Nordisk position peaked at $8.3M in Q2 2024.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.